WE ARE IMMERSIVE LIMITED

Financial Health Score: F (Terminal)

Explanation: The patient has been pronounced deceased. The company status is officially listed as "Dissolved," meaning the corporate entity has ceased to exist. While the 2024 financial statements show a remarkable, sudden improvement in net assets, this is the equivalent of a post-mortem cosmetic alteration—a financial restructuring that occurred right before the company's closure. The underlying operational pulse was critically weak, characterized by chronic historical losses and severe cash anemia.

Key Vital Signs

1. Corporate Body Temperature (Company Status): Dissolved. The corporate heartbeat has stopped. The company is no longer legally operating, with a dissolution date set for 2026.

2. Blood Pressure (Liquidity & Working Capital): Artificially Stabilized. Net Current Assets (working capital) jumped to £131,435 in 2024, up from a perilous £87 the year prior. However, this "blood pressure" spike is misleading. Current Assets are heavily bloated by £356,905 in "Other Debtors" (a symptom often associated with intercompany loans or director balances rather than realizable trading income), while actual cash in the veins is a dangerously anemic £16,364.

3. Circulatory Health (Cash Position): Critically Anemic. For a company employing 20 people, a cash balance of £16,364 is dangerously low. This suggests the business was burning through cash rapidly and surviving on life support (financing) rather than generating healthy cash flow from operations.

4. Body Mass Index (Net Assets & Capital Structure): Miraculous but Suspicious Gain. Net assets swung from a staggering deficit of -£400,017 in 2023 to a positive £461,602 in 2024. This £860k turnaround was not achieved through trading profit, but through a massive £1.78 million share capital injection (up from just £198 the prior year). This is a classic "debt-for-equity swap"—converting what was likely £800k+ of "Other Creditors" (loans) into share capital to clear the balance sheet.

5. Medical History (Accumulated Losses): Deep Scarring. Despite the capital injection, the Profit & Loss reserve shows a hemorrhage of -£1,318,563. The patient has a long history of bleeding red ink, which the recent capital injection cannot entirely erase from the historical record.

Diagnosis

The Corporate Autopsy: A Restructuring Prior to Closure

We Are Immersive Limited presents a fascinating clinical picture: a patient that appeared to cure a chronic, multi-year illness just before passing away.

From 2017 to 2023, the company suffered from severe chronic insolvency, with net assets deeply in the red (reaching -£400k in 2023). The primary symptoms were mounting "Other Creditors" (likely director or shareholder loans) and accumulating P&L losses.

In the 2024 fiscal year, the directors performed major surgery: a £1.78 million capital injection. This simultaneously achieved two things: it wiped out the massive short-term "Other Creditor" debt (which dropped from £466k to £112k) and eliminated the long-term creditor debt (which dropped from £439k to £0), flipping the net assets to a positive £461k.

However, while the balance sheet was surgically cleaned up, the operational organs were failing. Trade debtors (money owed by real customers) were a mere £13,895, while the company was aggressively capitalizing £327k of development costs. Capitalizing development costs while dissolving is akin to writing a cheque for a new house when you've already been evicted—it inflates the asset base but is unlikely to yield future economic benefit. The ultimate diagnosis is that the directors cleaned up the balance sheet to facilitate a tidy, solvent closure, rather than allowing the company to die an uncontrolled, insolvent death.

Recommendations

While the patient is unfortunately beyond saving, there are important post-mortem steps and lessons for the directors/shareholders:

1. Asset Realization (Collecting the Estate): The primary focus must now be on collecting the £356,905 in "Other Debtors." If these are director loan accounts, they must be repaid to the company before final distribution to shareholders can occur.
2. Intangible Asset Write-offs: The £287,487 in capitalized development costs should be evaluated for impairment. Given the dissolution, these software/VR assets are unlikely to generate future revenue and may need to be written off against the share capital before final striking off.
3. Final Tax Clearance: Ensure all final Corporation Tax returns are filed and settled with HMRC, particularly regarding any Research & Development (R&D) tax relief claims that may have been made on the capitalized development costs.
4. Director Health Check: For future ventures, the directors should reflect on the cash flow management of this entity. Growing headcount from 15 to 20 while holding less than £17k in cash is a symptom of aggressive, unsustainable growth that outpaced the circulatory system (cash flow).